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Results of the MRI Substudy of the Intravenous Magnesium
Efficacy in Stroke Trial
Chelsea S. Kidwell, MD; Kennedy R. Lees, MD; Keith W. Muir, MD; Christopher Chen, MD;
Stephen M. Davis, MD; Deidre A. De Silva, MD; Christopher J. Weir, PhD; Sidney Starkman, MD;
Jeffry R. Alger, PhD; Jeffrey L. Saver, MD; for the MR IMAGES Investigators
Background and Purpose—Although magnesium is neuroprotective in animal stroke models, no clinical benefit was
confirmed in the Intravenous Magnesium Efficacy in Stroke (IMAGES) trial of acute stroke patients. The Magnetic
Resonance in IMAGES (MR IMAGES) substudy investigated the effects of magnesium on the imaging surrogate
outcome of infarct growth.
Methods—IMAGES trial patients in participating centers were randomized to receive either intravenous magnesium or
placebo within 12 hours of stroke onset. Infarct growth was defined as volume difference between baseline
diffusion-weighted imaging and day 90 fluid-attenuated inversion recovery image lesions. Patients who died were
imputed the largest infarct growth observed.
Results—Among the 90 patients included in the primary analysis, there was no difference in infarct growth (median
absolute growth, P0.639; median percentage growth, P0.616; proportion with any growth, P0.212) between the
46 treated with magnesium and 44 with placebo. Infarct growth correlated with NIHSS score change from baseline to
day 90. There was a trend showing baseline serum glucose correlated with infarct growth with magnesium treatment,
but not in the placebo group. The mismatch frequency was reduced from 73% to 47% by increasing the mismatch
threshold from 20% to 100% of core volume.
Conclusions—Infarct growth, confirmed here as a surrogate for clinical progression, was similar between magnesium and
placebo treatment, paralleling the main IMAGES trial clinical outcomes. Glucose was a covariate for infarct growth with
magnesium treatment. A more stringent mismatch threshold to define penumbra more appropriately would have
excluded half of the patients in this 12-hour time window stroke study. (Stroke. 2009;40:1704-1709.)
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Neuroprotective therapies for acute ischemic stroke arepostulated to work by salvaging the ischemic penumbra
that surrounds the infarct core. More than 100 randomized,
clinical trials of neuroprotective therapies have been per-
formed in humans in the acute stroke setting.1 Despite
promising results in the laboratory setting, no neuroprotective
agent to date has been definitively shown to be of clinical
benefit in humans with acute ischemic stroke.2,3
The desired outcome and hence gold-standard measure-
ment of efficacy in human clinical stroke trials is neurological
and functional improvement. One barrier to demonstrating
the efficacy of neuroprotective agents in human phase III
clinical trials is the need to evaluate large numbers of patients
to demonstrate their modest clinical effect.2 There is a
pressing need for biologically based surrogate endpoints that
can discern treatment effects using smaller sample sizes. Such
intermediate surrogate endpoints could be used in phase II
clinical trials to rapidly identify and screen promising agents
in a cost-effective manner.4 These surrogate measures could
also be helpful in phase III clinical trials by providing
physiological evidence and offering biological plausibility for
efficacy of neuroprotective agents.
MRI offers promise as a surrogate outcome measure in
acute stroke trials.5 MR diffusion-weighted imaging (DWI)
and perfusion weighted imaging (PWI) visualize brain re-
gions of bioenergetic and blood flow compromise almost
immediately after ischemia onset.6 DWI combined with PWI
can provide an approximation of the extent of the ischemic
Received September 16, 2008; final revision received November 13, 2008; accepted November 20, 2008.
From Georgetown University (C.S.K., D.A.D.), Washington DC; University of California (C.S.K., S.S., J.R.A., J.L.S.), Los Angeles, Calif; Western
Infirmary (K.R.L.), Faculty of Medicine, University of Glasgow, Scotland; Division of Clinical Neurosciences (K.W.M.), University of Glasgow,
Scotland; National University of Singapore (C.C.), Singapore; National Medical Research Council (C.C., D.A.D.), Singapore; Royal Melbourne Hospital
(D.M.D.), Victoria, Australia; University of Melbourne (S.M.D.), Australia; National Neuroscience Institute (D.A.D.), Singapore General Hospital
campus, Singapore; Robertson Centre for Biostatistics (C.J.W.), University of Glasgow, Scotland.
Correspondence to Chelsea S. Kidwell, Building D, Suite 150, Georgetown University, 4000 Reservoir Road, NW, Washington DC, 20007. E-mail
ck256@georgetown.edu
© 2009 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.108.537613
1704
penumbra.6 Therapeutic salvage of the penumbral region has
been demonstrated on MRI studies in humans with acute
stroke.7–9 Serial imaging studies allow quantification of
infarct growth over time and, therefore, an assessment of
whether a therapeutic agent prevents progression of infarction
in the penumbral region. The approach of measuring infarct
growth closely parallels the pathological ascertainment of
infarct volume as a standard gauge of therapeutic efficacy in
animal stroke models. Moreover, in humans, infarct growth
after ischemic stroke has been shown to closely correlate with
poor clinical outcome.7,9–12 However, attenuation of ischemic
DWI lesion growth with neuroprotective agents has to date
only been definitively demonstrated in animal models.2
The Intravenous Magnesium Efficacy in Stroke (IMAGES)
trial was designed to test whether intravenous magnesium
sulfate, administered within 12 hours of stroke onset, reduces
death or disability at 90 days.13 Preclinical trials,14,15 as well
as pilot trials,16–20 in humans suggested that magnesium has
a neuroprotective effect in ischemic stroke. However, in the
main IMAGES trial, clinical outcome at day 90 with magne-
sium did not differ significantly from placebo. The MRI
substudy was undertaken after the main trial had begun to
provide an auxiliary biological measure of drug effect. The
primary hypothesis tested in this substudy was that magne-
sium sulfate attenuates infarct growth, as measured from
baseline DWI volume to day 90 infarct volume, among
enrolled ischemic stroke patients.
Patients and Methods
Patient Selection
MR IMAGES was a multicenter, double-blind, randomized, placebo-
controlled clinical trial designed as a substudy within the larger
IMAGES trial.21 Between January 2000 and October 2003, 8 centers
in 5 countries participated in the MRI substudy. Randomization in
the MRI substudy was allowed to continue beyond the end of
recruitment to the main trial, up to the time of unblinding of
IMAGES data. At that point, the Steering Committee and Data
Safety and Monitoring Board opted to close enrollment in the MRI
substudy, even though the target sample size had not been reached.
Inclusion and exclusion criteria for the MRI substudy were identical
to those of the main IMAGES trial,13 except for additional imaging-
related criteria. A minimum DWI lesion volume was prespecified for
enrollment, initially 5 mL, which was altered to 3 mL during
recruitment. Patients were excluded for the following reasons:
pacemaker or other metal implant precluding MRI study; history of
second- or third-degree heart block; recent stroke within previous 30
days or rapidly resolving deficit; and known allergic reaction to MRI
contrast (gadolinium).
Enrollment into the MRI substudy occurred via the interactive
voice–response system used for the main IMAGES trial. Study drug
administration also proceeded as described in the main IMAGES
trial manuscript.13 Serum glucose was measured at baseline before
drug administration. Clinical outcome measures collected included
NIHSS at baseline, 48 hours, and day 90, as well as the Barthel index
and modified Rankin score at day 90. Patient who died were
allocated a day 90 NIHSS score of 42. Poor clinical outcome was
defined by global score of Barthel index 95 or modified Rankin
score 1; Barthel index 95; Barthel index 60; modified Rankin
score 1; and death.13
The substudy was overseen by the IMAGES trial Data Safety and
Monitoring Board until enrollment was closed in the main trial. After
that time, a substudy-specific medical monitor was appointed (K.M.)
and an independent Data Safety and Monitoring Board was estab-
lished. The substudy was approved by the institutional review board
at each site and informed consent was obtained for all patients
enrolled.
Imaging Methods and Outcome Measures
All substudy sites were required to have MRI scanners capable of
performing DWI. MRI was performed at screening and day 90. The
screening MRI included the following sequences: a T1-weighted
sagittal scout, DWI, and, when available, PWI (T2*-weighted
imaging for bolus tracking perfusion images). The day 90 study
included scout, DWI, and fluid-attenuated inversion recovery se-
quences. Recommended sequence parameters were provided to sites
to standardize imaging methodology. Images were sent to the UCLA
core imaging laboratory for processing and analysis. Imaging anal-
yses were performed by a single reader (C.S.K.) blinded to treatment
assignment and clinical information.
The following regions of interest were outlined using a semiau-
tomated segmentation technique: baseline DWI lesion volume,
baseline perfusion lesion volume defined as the region within the
involved vascular territory with a Tmax (time-to-peak of the residue
function) value 2 seconds, and day 90 infarct volume on fluid-
attenuated inversion recovery sequence (if fluid-attenuated inversion
recovery was not obtained, a T2-weighted sequence was used). For
each patient, infarct growth was measured by absolute lesion growth
(day 90 lesionbaseline DWI lesion volume); percentage lesion
growth ([day 90 lesionbaseline DWI lesion volume]baseline
DWI lesion volume100%); and growth dichotomized as 0% and
0% percentage lesion growth. A conservative adjustment measure
was used to correct for possible bias effects from patients who left
the study because of death—these patients were imputed to have the
largest infarct growth among subjects with day 90 imaging. Seven-
teen patients with initial DWI lesions less than the entry criteria (3
mL) were enrolled, and they were retained in the primary intention-
to-treat analysis. Separate analyses were performed for subgroups of
patients with clinically defined lacunar stroke using the Oxfordshire
Community Stroke Project classification system22; imaging-defined
lacunar stroke (small, deep infarct 1.5 cm in diameter without
evidence of large-vessel territory involvement on DWI or PWI
sequences); baseline DWI lesion volume 3 mL; diffusion–perfu-
sion mismatch ([PWI-DWI]/DWI lesion volume) 20%; both base-
line DWI lesion volume 3 mL as well as 20% diffusion–
perfusion mismatch; and treatment within 6 hours of symptom onset.
After a publication23 based on the Diffusion and Perfusion Imaging
Evaluation for Understanding Stroke Evolution (DEFUSE) study
cohort that suggested that the optimal mismatch threshold should be
raised 20%, we also studied a subgroup with diffusion–perfusion
mismatch 100%. This cut-off was chosen as a compromise between
the cut-off of 160% (which optimally predicted favorable clinical
outcome with early perfusion but severely restricted the number of
patients) and 80% (which was suggested as less restrictive).23
Statistical Analysis
The prespecified primary study end point was infarct growth from
baseline DWI to day 90 final lesion volume in the intent-to-treat
population. Group differences were analyzed using the Mann-
Whitney U test for continuous variables and the 2 test or Fisher
exact test for binary variables. Statistical significance of possible
interactions was studied using logistic regression for categorical
outcomes and 2-way ANOVA testing for continuous outcomes.
The target sample size of 150 patients was calculated based on the
following assumptions: (1) 85% survival at day 90 in the placebo
group and (2) magnesium effect estimated as 25% reduction of
infarct growth, conservatively derived from animal studies that show
magnesium reduces infarct volume by 29% to 65%.14,24,25 The
sample size necessary to detect a 25% difference in infarct growth
using a 2-tail test with alpha0.05 and power80% was calculated
to be 72 in each treatment arm.
Results
A total of 104 patients were enrolled in the MR IMAGES
study (Figure). Pretreatment imaging data could not be
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analyzed in 6 patients. Of the 98 patients with baseline
imaging data available, 74 underwent a day 90 MRI. Among
the patients alive at day 90 but without outcome MRI (8
placebo, 8 magnesium), the final Barthel and modified
Rankin score scores did not differ from those with final
outcome scanning. As prespecified, maximum lesion growth
(183% for percentage growth; 214 mL for absolute growth)
was assigned to patients who died before their day 90 scan.
Therefore, there were 90 patients in the primary outcome
analysis (44 placebo, 46 magnesium). Among patients who
were alive at day 90, Barthel index was ascertained for 70
patients (34 placebo, 36 magnesium) and modified Rankin
score in 86 (42 placebo, 44 magnesium).
Mean time to treatment across the 90 patients was 7 hours
52 minutes (SD, 2 hours 30 minutes; range, 2 hours 15
minutes to 11 hours 50 minutes). Only 2 patients were
enrolled 3 hours and 26 patients 6 hours from onset.
Median NIHSS score was 12 (range, 2–28). Median baseline
DWI lesion volume was 21 mL (range, 0–303 mL). Seventy-
one patients had a baseline DWI lesion 3 mL. Of the 60
patients with baseline perfusion imaging available for analy-
sis, median baseline PWI lesion volume was 79 mL (range,
0–438 mL) and median baseline DWI volume was 24 mL
(range, 0–290 mL). The proportion of patients with perfu-
sion–diffusion mismatch decreased from 73% (44/60), using
a threshold of 20%, to 47% (28/60), using a threshold of
100%. Median day 90 infarct volume was 14 mL (range,
0–531 mL). Fifty-one patients (57% of 90) had percentage
infarct growth 0% from the baseline to the day 90 scan.
Among the 90 patients with outcome data, baseline DWI
lesion volume correlated with baseline NIHSS (Spearman
correlation coefficient0.669; P0.001) and final infarct
size (Spearman correlation coefficient0.948; P0.001).
Absolute lesion growth (Spearman correlation coeffi-
cient0.654; P0.001), as well as percentage lesion growth
(Spearman correlation coefficient0.581; P0.001) both
correlated with change of the NIHSS score from baseline to
day 90. Among the 60 patients with baseline PWI performed,
baseline PWI lesion volume correlated with baseline NIHSS
(Spearman correlation coefficient0.499; P0.001) and fi-
nal infarct volume (Spearman correlation coefficient0.805;
P0.001). There were also correlations between mismatch
volume with final infarct volume (Spearman correlation
coefficient0.382; P0.003) and infarct growth volume
(Spearman correlation coefficient0.234; P0.027).
For the 90 patients contributing to the primary analysis,
there were no significant differences between magnesium and
placebo groups in baseline characteristics (Table 1). There
were 18 patient with clinically defined lacunar stroke (9
placebo, 9 magnesium) and 15 patients with imaging-defined
lacunar stroke (9 placebo, 6 magnesium).
Among the 90 intention-to-treat patients, there were no
significant differences between magnesium and placebo treat-
ment in the primary outcome measure of infarct growth using
various measurements (Table 2). There were also no differ-
ences in clinical outcomes between treatment groups. For the
groups of patients who fulfilled the prespecified criterion of
DWI lesion 3 mL, there was no difference between mag-
nesium and placebo treatment in terms of absolute growth,
percentage growth, and proportion with growth0% (Table 3).
Exploratory analyses failed to demonstrate any significant
difference for infarct growth between placebo and magne-
Patients enrolled = 104 
Baseline DWI imaging available = 98 
Target volume ≥3 cc = 71 
PWI data available = 60 
Placebo = 
44 
Corrupted or lost data = 6 
Day 90 assessment = 90 
Day 90 imaging available = 74 
Died and assigned maximum lesion 
growth = 16 
Declined day 90 imaging or lost to 
follow-up = 7 
Pacemaker inserted = 1 
Magnesium 
Sulphate = 
46 
Figure. Flow chart and patient treatment assignment.
Table 1. Baseline Characteristics of Subjects in Whom
Primary Hypothesis Was Tested
Placebo n44 Magnesium n46
Mean age, yr, SD 6914 6515
Female 43% (19) 43% (20)
Hypertension 73% (32) 59% (27)
Diabetes 30% (13) 30% (14)
Hyperlipidemia 20% (9) 20% (9)
Smoking 25% (11) 17% (8)
Atrial fibrillation 23% (10) 22% (10)
Ischemic heart disease 27% (12) 17% (8)
Previous stroke 14% (6) 22% (10)
Previous TIA 9% (4) 11% (5)
Median NIHSS (IQR) 13 (7–19) 12 (7–18)
Median DWI lesion volume, mL (IQR) 24 (3–80) 11 (4–50)
Median PWI lesion volume, mL (IQR),
n60
80 (28–198) 73 (4–261)
Median mismatch volume, mL (IQR),
n60
2 (2–98) 1 (7–59)
Mismatch percentage (%), n60
(IQR)
63 (1–230) 78 (5–363)
Median time from onset to
enrollment, min (IQR)
465 (368–596) 498 (330–630)
Median serum glucose, mg/dL (IQR) 133 (111–185) 124 (109–165)
Median mean arterial pressure,
mm Hg (IQR)
113 (99–123) 105 (94–114)
Clinically defined lacunar stroke 20% (9) 20% (9)
Imaging-defined lacunar stroke 21% (9) 13% (6)
IQR indicates interquartile range.
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sium treatment for the following subgroups: clinically de-
fined lacunar stroke, imaging-defined lacunar stroke, patients
with diffusion–perfusion mismatch20%, patients with both
baseline DWI lesion volume 3 mL as well as diffusion–
perfusion mismatch, and patients treated within 6 hours of
symptom onset (supplemental Table I, available online at
http://stroke.ahajournals.org). Using the prespecified global
clinical outcome measure, percentage infarct growth
(P0.015) and absolute infarct growth (P0.004) were
greater among patients with poor global clinical outcome.
The proportion with infarct growth 0% was also higher
among patients with poor global clinical outcome (4% vs
42%; P0.084).
Baseline glucose levels were available for 88 of the 90
intention-to-treat patients. The median baseline serum glu-
cose level was 7.1 mmol/L (128 mg/dL), with a range of 3.4
to 22 mmol/L (62–396 mg/dL). Among all patients, serum
glucose correlated significantly with absolute (P0.028) and
percentage (P0.024) growth; however, the higher serum
glucose among patients with growth 0% was not statisti-
cally significant (P0.103; Table 4). Serum glucose also
correlated with absolute growth (P0.012) and percentage
growth (P0.048) for the magnesium-treated group. In the
magnesium-treated group, serum glucose trended higher
among patients with growth 0% compared to patients with
growth 0% (P0.064).
However, in the placebo group, serum glucose did not
correlate as strongly with absolute (P0.498) or percentage
(P0.233) infarct growth. Among placebo-treated patients,
there was no significant difference between patients with
growth 0% and growth 0% (P0.552). Using logistic
regression, the interaction of baseline glucose level and
treatment allocation tended to predict infarct growth 0%
(P0.071), independent of baseline glucose level and treat-
ment allocation alone.
Discussion
The results of the MR IMAGES substudy are consistent with
the findings of the main IMAGES clinical trial13: no signif-
icant difference was demonstrated in infarct growth between
placebo and magnesium-treated groups. Although the sample
target size was not reached, the current data do not suggest
that the results would have differed for the primary analysis
with recruitment of additional patients.
Our study provides further evidence that imaging lesion
volumes are good surrogates for clinical outcome. As previ-
ously shown,26 both acute DWI and PWI lesion volumes
correlated well with baseline neurological status. Infarct
growth was confirmed as a good surrogate for clinical
neurological progression, here measured as a change in
NIHSS from baseline to day 90, consistent with published
literature.7–10 The weaker correlations of final infarct volume
with PWI and mismatch lesion volumes, compared to DWI
lesion volume, support previously published opinions that
mismatch does not optimally define the penumbra.27,28 A
perfusion deficit with Tmax 2 seconds has been shown to
include areas of benign oligemia, which are not at risk for
proceeding to infarction.27,29,30
Most studies using mismatch as an inclusion criteria,
including the Echoplanar Imaging Thrombolytic Evaluation
Trial (EPITHET),9 the DEFUSE study,8 the Desmoteplase in
Acute Ischemic Stroke (DIAS) trial,31 and the Dose Escala-
tion of Desmoteplase for Acute Ischemic Stroke (DEDAS)
trial,32 used a mismatch threshold of 20%. Post hoc analy-
ses of the DEFUSE study population found that a higher
mismatch threshold of 80% more than doubled the odds of
a favorable clinical response with early reperfusion.23 The
Table 2. Primary Hypothesis Findings
Placebo n44 Magnesium n46 P
Primary hypotheses finding
Median absolute growth,
mL (IQR)
10 (2–66) 1 (2–69) 0.639
Median percentage growth,
% (IQR)
5 (39–80) 26 (41–113) 0.616
Growth 0% 50% (22/44) 63% (29/46) 0.212
Unfavorable global
outcome
79% (33/42) 77% (34/44) 0.885
Barthel score 60 35% (12/34) 31% (11/36) 0.673
Barthel score 95 65% (22/34) 67% (24/36) 0.863
Modified Rankin score 1 71% (30/42) 73% (32/44) 0.893
Death 18% (8/44) 17% (8/46) 0.922
Table 3. Growth Outcomes Among Patients With Baseline
DWI Lesions >3 mL
Placebo n33 Magnesium n40 P
Median absolute growth,
mL (IQR)
14 (3–214) 3 (2–99) 0.951
Median percentage growth,
% (IQR)
36 (18–140) 28 (33–138) 0.659
Growth 0% 61% (20/33) 65% (26/40) 0.699
Table 4. Univariate Associations/Correlations of Serum
Glucose With Growth
P
All patients
Absolute growth 0.234* 0.028
Percentage growth 0.241* 0.024
Growth 0% 7.4 (6.3 to 10.1) mmol/L† 0.103
Growth 0% 6.5 (5.5 to 8.4) mmol/L†
Magnesium group
Absolute growth 0.373* 0.012
Percentage growth 0.296* 0.048
Growth 0% 7.4 (6.2 to 10.5) mmol/L† 0.064
Growth 0% 6.3 (5.4 to 7.6) mmol/L†
Placebo group
Absolute growth 0.106* 0.498
Percentage growth 0.188* 0.233
Growth 0% 7.4 (6.4 to 9.9) mmol/L† 0.552
Growth 0% 6.9 (5.7 to 10.6) mmol/L†
*Spearman correlation coefficient for serum glucose.
†Median serum glucose (IQR).
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reduction of the included group from 73% to 47% by raising
the mismatch threshold from 20% to 100% suggests that
more than half of the patients in MR IMAGES population
may not have had an appropriate penumbral pattern with
potentially salvageable tissue. This is an important finding
which may explain the negative results of studies with
mismatch inclusion of 20% investigating the effect of
intravenous tissue plasminogen activator in the 3- to 6-hour
window (EPITHET9) and intravenous desmoteplase up to 9
hours after symptom onset (DIAS31 and DEDAS32). Future
studies should consider alternative approaches to defining the
penumbra, pending further post hoc analysis from the EPI-
THET, DEFUSE, and DEDAS trials.
Proof-of-concept trials using surrogate imaging outcomes
may be useful in determining the feasibility of large phase III
trials with clinical endpoints, testing the physiological effects
of a drug with fewer patients and identifying subgroups of
patients or possible covariates.5 Whereas studies of reperfu-
sion therapies have demonstrated attenuated infarct growth
and that this attenuation correlates with improved clinical
outcome,9 there has been such positive trials testing neuro-
protective agents. A phase II trial testing the neuroprotective
effect of magnesium infusion in acute stroke using imaging
surrogate outcomes would have likely yielded similar results
as found in this study. Thus, a phase II proof-of-concept study
designed similarly to the MR IMAGES substudy would have
likely demonstrated no difference between magnesium and
placebo groups in imaging surrogate outcome of infarct
growth. Such a proof-of concept study would have provided
important insights and may have influenced the decision to
proceed with the main IMAGES study.
A published further analysis of the IMAGES trial found
that magnesium improved clinical outcome among patients
with lacunar clinical syndromes.33 In this MRI substudy, we
did not find any significant treatment-related differences in
imaging outcome measures among patients with clinically
defined lacunar syndrome and imaging-defined lacunar in-
farction. Possible reasons for these differing results are the
very small number of patients with lacunar stroke and the
known propensity for errors in infarct growth measurement
for small lesions.34 None of the other subgroup analyses
revealed any difference in infarct growth among treatment
groups.
The deleterious effect of hyperglycemia on infarct growth
in the overall group concurs with published literature35–37
showing that hyperglycemia is associated with poorer imag-
ing and clinical outcomes in acute stroke. There was a trend
toward greater negative influence of higher serum glucose on
infarct growth with magnesium treatment compared to its
effects with spontaneous infarct growth in the placebo group.
Although not statistically significant, this finding is intrigu-
ing. The neuroprotective effect of magnesium chloride was
attenuated by hyperglycemia in an animal model, as dem-
onstrated by compensation with insulin coadministration.14
No effect of magnesium sulfate on glucose levels has been
noted in animal models, multiple clinical trials in preg-
nancy, myocardial ischemia, and brain injury, or in clinical
practice.38
The limitations of this investigation include the shortcom-
ings of studies with imaging outcomes such as corrupted/lost
data and need to use imputed volumes for patients who died
before day 90. In addition, there is no established best
measure for infarct growth, hence we used 3 measures in this
substudy, absolute growth in mL, percentage growth, and
growth dichotomized for the presence of any growth 0%.
Third, we did not reach the planned sample size. Fourth, 19%
of patients enrolled did not fulfill the prespecified criterion of
DWI lesion 3 mL. Finally, we had only 1 measurement of
glucose. Persistent hyperglycemia after stroke has been
shown to be a better indicator of infarct evolution and clinical
outcome compared to any isolated measurement.39
Summary
In conclusion, the lack of treatment effect on infarct growth in
this MR substudy concurs with the clinical outcome finding
in the main IMAGES study. These data, together with the
confirmation that infarct growth correlates with clinical
progression, support use of imaging surrogates in proof-of-
concept studies before larger-scale clinical trials. An impor-
tant secondary finding from this randomized imaging-based
substudy is that a more appropriate mismatch threshold
would exclude a sizeable proportion of patients in prior acute
stroke trials using mismatch selection.
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